NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00180882,LMBA02 Protocol for Patients With a Burkitt Lymphoma,https://clinicaltrials.gov/study/NCT00180882,,UNKNOWN,To explore in a multicenter international prospective randomized study (phase III) whether rituximab combined with the standard French LMB chemotherapy scheme results in a higher rate of EFS than the LMB chemotherapy scheme alone in patients older than 18 years with Burkitt lymphoma or ALL 3.,NO,Burkitt Lymphoma,DRUG: rituximab,Event free survival from date of first randomization,"Complete and partial response rate, overall survival, toxicity",,"Gustave Roussy, Cancer Campus, Grand Paris",,ALL,"ADULT, OLDER_ADULT",PHASE3,260,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,LMBA02,2004-10,,,2005-09-16,,2006-09-11,"Institut Gustave Roussy, Villejuif, 94800, France",
